Stock Price & Analysis

Based on recent analyst upgrades and market data, Charles River Laboratories (CRL) appears to be stabilizing after a period of weakness, though caution is still warranted. Two major investment firms have recently upgraded CRL from Sell to Neutral:

Recent Key Developments:

• Redburn Atlantic upgraded to Neutral with $188 target, citing stabilization in Discovery and Safety segment
• Citi upgraded to Neutral with $175 target, noting better investor understanding of challenges

Current Market Position:

• Stock has shown signs of stabilization after significant underperformance
• Discovery and Safety segment appears to be finding support after sustained weakness
• Price and mix headwinds expected to continue throughout 2025

Technical Analysis:

• Stock entered oversold territory in January 2025 with RSI reading of 27.2
• Key support level around $160.85 (52-week low)
• Resistance levels at $175-188 based on recent analyst targets

Recommendation: Based on recent analyst upgrades and stabilizing fundamentals, holding CRL stock appears more prudent than selling at current levels, though immediate upside may be limited due to ongoing sector headwinds and pricing pressures.

Based on the provided data and recent analyst updates, here's the price prediction for Charles River Laboratories (CRL) stock in 2025:

Charles River Laboratories' stock is expected to trade in the range of $175-$188 by mid-2025, with analysts recently upgrading their outlook from Sell to Neutral. The primary drivers for this prediction are the stabilization in demand within the Discovery and Safety segment after a period of weakness, and improved investor understanding of challenges related to large pharma customers and pipeline restructuring.

The company's implementation of cost-saving initiatives, including a 6% headcount reduction and footprint optimization, is expected to yield $200 million in annualized savings by 2026. However, the company faces continued pricing and mix headwinds in its Discovery and Safety Assessment segment throughout the year.

The S1 support level for CRL Stock is $163.14 ,The R1 resistant level for CRL Stock is $174.78.

As of the end of day on 2025-03-10, the price of CRL Stock was $174.

The target price for CRL Stock according to analyst rating is 177.62, with the highest price target at 190.00 and the lowest at 165.00. Analysts have a Hold rating on CRL Stock overall.

The market cap of CRL is $9.0B.

Based on recent analyst reports, Charles River (CRL) appears fairly valued at current levels, with multiple analysts upgrading the stock from Sell to Neutral. The company's Discovery and Safety segment has shown signs of stabilization after a period of weakness, though pricing and mix headwinds are expected to persist throughout the year. Recent price target adjustments from analysts ($175-188) suggest limited downside risk from current levels, with the market now better understanding challenges related to large pharma customers and pipeline restructuring. The stock's recent underperformance has brought valuations to more reasonable levels, though significant upside catalysts remain limited in the near term.

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Based on the available data and market analysis, here's the 2030 price prediction for Charles River Laboratories (CRL) stock:

Charles River Laboratories stock is projected to reach $245-265 by 2030, driven by the company's restructuring initiatives targeting $200 million in cost savings by 2026 and its dominant position in pre-clinical trials where it has worked on over 80% of approved pharmaceutical products. However, this growth will likely be moderated by ongoing challenges in the Discovery and Safety Assessment segment and potential disruptions in non-human primate supply chains.

The company's focus on operational efficiency and strategic consolidation of facilities should help restore margins and support long-term value creation, though near-term headwinds from constrained biopharma spending will persist through 2025-2026.

CRL has a total of 20000 employees.